Lung Cancer
News
Early results positive for nivolumab as first-line therapy in advanced NSCLC
Key clinical point: A phase I trial indicates that nivolumab is safe and shows durable activity as a first-line therapy in treating patients with...
News
Nivolumab plus chemo shows increased response, decreased safety in NSCLC
Key clinical point: Nivolumab administered in combination with platinum-based doublet chemotherapy may improve response rates. However, the...
Conference Coverage
Wedge resection showed improved survival over SBRT for early-stage NSCLC
Key clinical point: Wedge resection outperformed SBRT in terms of mortality for early-stage NSCLC. Major finding: In matched groups, SBRT was...
News
Early results promising for pembrolizumab in combination regimens for NSCLC
Key clinical point: Overall response rates ranged from 30% to 71% when pembrolizumab was added to chemotherapy combinations or paired with an R2...
From the Journals
IASLC lung cancer staging project proposes changes for new TNM classification
Key clinical point: New lung cancer classification to become effective January 2017. Major finding: Size will now be a descriptor in all T...
News
Better pembrolizumab outcomes with increasing PD-L1 in NSCLC
Key clinical point: Pembrolizumab is superior to docetaxel in patients with non–small cell lung cancer especially at higher TPS. PD-L1 may be a...
News
Study results differ on benefits of proton radiotherapy in NSCLC
Key clinical point: Results of a small randomized trial and an analysis of the National Cancer Data Base show conflicting results about the...
News
Dual checkpoint blockade doubles response in SCLC
Key clinical point: Adding ipilimumab to nivolumab resulted in better responses in SCLC than nivolumab alone. Major finding: Among 216 patients,...
Conference Coverage
Web app boosts lung cancer survival
Key clinical point: A Web-based app improves survival for advanced lung cancer patients. Major finding: Survival improved by 26% for web-app...
News
Vandetanib shows variable response, toxicity in RET-positive NSCLC
Key clinical point: Vandetanib shows marked yet variable anti-tumor activity and toxicity in patients with RET-rearranged NSCLC. Major finding:...